KAKatsumi Amikura

Katsumi Amikura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Katsumi Amikura has a total of 107 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • ASO Visual Abstract: Optimal Region of Lymph Node Dissection in Distal Pancreatectomy for Left-sided Pancreatic Cancer Based on Tumor Location

    by Hiroyuki Ishida, Toshiro Ogura, Amane Takahashi, Ryoichi Miyamoto, Shinichi Matsudaira, Katsumi Amikura, Minoru Tanabe, Yoshiyuki Kawashima


  • The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: The results from a genetic analysis of all‐RAS

    by Katsumi Amikura, Kiwamu Akagi, Toshiro Ogura, Amane Takahashi, Hirohiko Sakamoto

    Introduction: We investigated the impact of mutations in KRAS exons 3‐4 and NRAS exons 2‐3 in addition to KRAS exon 2, so‐called all‐RAS mutations, in patients with colorectal liver metastasis (CLM) undergoing hepatic resection.Methods: We analyzed 421 samples from CLM patients for their all‐RAS mutation status to compare the overall survival rate (OS), recurrence‐free survival rate (RFS), and the pattern of recurrence between the patients with and without RAS mutations.Results: RAS mutations were detected in 191 (43.8%). Thirty‐two rare mutations (12.2%) were detected in 262 patients with KRAS exon 2 wild‐type. After excluding 79 patients who received anti‐EGFR antibody therapy, 168 were classified as all‐RAS wild‐type, and 174 as RAS mutant‐type. A multivariate analysis of factors associated with OS and RFS identified the RAS status as an independent factor (OS; hazard ratio [HR] = 1.672, P = 0.0031, RFS; HR = 1.703, P = 0.0024). Recurrence with lung metastasis was observed significantly more frequent in patients with RAS mutations than in patients with RAS wild‐type (P = 0.0005).Conclusions: Approximately half of CLM patients may have a RAS mutation. CLM patients with RAS mutations had a significantly worse survival rate in comparison to patients with RAS wild‐type, regardless of the administration of anti‐EGFR antibody therapy.


  • Preclinical study of c-Met inhibitor as an adjuvant treatment for hepatocellular carcinoma with macroscopic portal vein invasion.

    by Takashi Kokudo, Yoshinori Inagaki, Kiyoshi Hasegawa, Chikara Shirata, Katsumi Amikura, Amane Takahashi, Junichi Kaneko, Nobuhisa Akamatsu, Junichi Arita, Yoshihiro Sakamoto, et al.

    301 Background: Patients with advanced hepatocellular carcinoma (HCC) demonstrating a macroscopic portal vein tumor thrombus (PVTT) have been reported to have an extremely poor prognosis. Palliative sorafenib is the only recommended treatment option. Methods: We statistically compared the patient characteristics and surgical outcomes in HCC patients with PVTT. Among 1,611 hepatic resections, 105 cases of PVTT were identified. Microarray analysis was performed in three patients to identify gene expression changes in PVTT compared with those in the principal tumor, and the changes were validated in 20 human HCC tissues with PVTT. The human HCC cell lines HuH-7 and SKHep-1 were used for this experimental study. A subcutaneously transplanted xenograft model was employed for the in vivo study. The c-Met inhibitor SU11274 was used in both in vitro and in vivoanalyses. Results: The median survival time in patients with PVTT was 2.01 years, while that in patients without PVTT was 6.43 years; the median time to recurrence was 0.31 and 1.61 years, respectively. Microarray analysis revealed 36 genes related to PVTT. Immunohistochemistry analysis revealed that compared with the principal tumor, E-cadherin (a key regulator of cancer metastatic potential) significantly decreased in PVTT in all 20 patients. The c-Met inhibitor elevated the E-cadherin expression level in HCC cells both in vitro and in vivo. This inhibitor induced sheet formation and attenuated the migration of HCC cells. Conclusions: Although liver resection provides acceptable overall survival for patients with PVTT, the recurrence rate remains high. The c-Met inhibitor exhibits an anti-metastatic effect in vitro and in vivo and may be useful as an adjuvant treatment for PVTT.


  • Assessment of preoperative liver function in patients with hepatocellular carcinoma: The albumin-indocyanine green evaluation (ALICE) grade.

    by Takashi Kokudo, Kiyoshi Hasegawa, Katsumi Amikura, Emilie Uldry, Chikara Shirata, Takamune Yamaguchi, Junichi Arita, Junichi Kaneko, Nobuhisa Akamatsu, Yoshihiro Sakamoto, et al.

    4066 Background: Most patients with hepatocellular carcinoma (HCC) have underlying liver disease, therefore, precise preoperative evaluation of the patient’s liver function is essential. Methods: We developed a simple grading system incorporating only two variables, namely, the serum albumin level and the indocyanine green retention rate at 15 minutes, to assess the preoperative liver function, based on the overall survival of 1868 patients with HCC who underwent liver resection. We then tested the model in a European cohort (n = 70) and analyzed the predictive power of the grading system for the postoperative short-term outcome in a Japanese cohort. Results: The Albumin-Indocyanine Green Evaluation (ALICE) grading system was developed in a randomly assigned training cohort: linear predictor = 0.663 × log10 ICG R15 (%) - 0.0718 × albumin (g/dL) (cut-off value: -2.20 and -1.39). This new grading system showed a predictive power for the overall survival similar to the Child-Pugh grading system in the validation cohort. Determination of the ALICE grade in Child-Pugh A patients allowed further stratification of the postoperative prognosis (median survival time: grade 1, 12.5 y; grade 2, 6.45 y; grade 3, 3.37 y). This result was reproducible in the European cohort. Determination of the ALICE grade allowed better prediction of the risk of postoperative liver failure and mortality (ascites: grade 1, 2.1%; grade 2, 6.5%; grade 3, 16.0%; mortality: grade 1, 0%; grade 2, 1.3%; grade 3, 5.3%) than the previously reported model based on the presence/absence of portal hypertension. The ALICE grade 2 was further divided into 2 groups (2a and2b) using the median linear predictor (-1.88) as a cut-off value. Although major resection did not affect the incidence of ascites or the mortality rate in the ALICE grade 2a group, major resection in the ALICE grade 2b group had a significantly higher incidence of ascites and mortality rate. Conclusions: This new grading system is a simple and objective method for prediction of the postoperative long-term and short-term outcomes. This new system could be potentially used worldwide for surgical decision making in patients with HCC.

  • Open Access

    A Case of a 75-year-old Man with Bile Duct Cancer and Cognitive Decline

    by Yoshihiro Miyazaki, Katsumi Amikura, Takashi Kokudo, Amane Takahashi, Yu Yamada, Hirohiko Sakamoto

    症例は75歳の男性で,黄疸を契機に胆管癌(cT2,N1,M0,cStage IIB)と診断され,減黄後に治療目的に当院を受診した.ADL低下と中等度の認知機能低下を伴っており,認知症とせん妄のどちらが原因かの鑑別が困難であったが,精神腫瘍科にコンサルトし,せん妄に伴う一過性の認知機能低下と診断し治療適応と判断した.また,早期からの多職種介入により,入院中から退院後までの充実したサポート体制を構築し,円滑に診療を進めた.患者背景や全身状態を考慮した上で縮小手術として肝外胆管切除術,リンパ節郭清を施行し,術後2年間無再発で外来通院中である.高齢化に伴い高齢手術患者が増加しているが,せん妄は高齢者で頻度が高く,認知機能低下を伴い認知症との鑑別が困難なことも多い.早期からの多職種の介入により円滑に診療を進めることが重要と考えられた.

  • Open Access

    A Case of a 10-year Survivor with Synchronous Liver Metastasis from Esophageal Carcinoma following Hepatectomy

    by Yumiko Kageyama, Katsumi Amikura, Takashi Fukuda, Takashi Kokudo, Amane Takahashi, Hirohiko Sakamoto

    症例は57歳の男性.胸部食道癌,肝S6に径18mm,単発の肝転移の診断で,右開胸開腹食道亜全摘,肝S6部分切除術を施行.術後病理診断は食道癌,pT3N2M1(肝),Stage IVbであった.術後補助化学療法としてFP療法を施行.術後5カ月目に小脳転移を認め,腫瘍切除後,全脳照射を施行した.FP療法を再開後,初回術後1年7カ月目で左肺転移1箇所,右腎転移1箇所を認め,DTX+CDGPに変更.その後,右腎転移は消失し,左肺転移に対して肺部分切除を施行した.以後は無治療で経過観察を行い,初回手術後10年4カ月現在,無再発生存中である.食道癌肝転移は多発症例や他臓器転移を伴う症例が多く予後不良であり,外科的切除の適応はないと考えられている.しかし,単発症例では長期生存例の報告もあり,外科的切除も検討すべきと考えられた.


    • 1 November 2015
      • Vol. 42  (12) , 1570-2

    [A Case of a Patient with Distal Bile Duct Carcinoma Who Underwent Surgical Resection Three Times for Pulmonary Metastases].

    by Katsumi Amikura, Hirohiko Sakamoto, Amane Takahashi, Toshiro Ogura, Kiyohiko Omichi, Hidetaka Uramoto, Hirohiko Akiyama, Hiroyasu Kinoshita, Yuki Nakajima, Kensei Yamaguchi, et al.

    A 63-year-old woman attended our hospital after diagnosis of a solitary pulmonary metastasis from a distal bile duct carcinoma. She had undergone a subtotal stomach-preserving pancreaticoduodenectomy 1 year 9 months prior to the current presentation. She was treated with right thoracoscopic pulmonary partial resection. The specimen was a solitary nodule 5 mm in diameter. In addition, she was treated with adjuvant chemotherapy involving GEM for 6 months. One year 5 months later, she was diagnosed with a second pulmonary metastasis and was treated with a left thoracoscopic partial resection. Four months later, she experienced recurrence in the right lung stump and was treated with right thoracoscopic partial resection. The specimen was a solitary nodule 21 mm in diameter. Cytopathologic examination of the pleural fluid resulted in a diagnosis of Class Ⅴ. She was treated with adjuvant chemotherapy involving TS-1 for 6 months. Seven months later, she was experienced recurrence with multiple pulmonary metastases and an affected hilar lymph node. GEM/CDDP chemotherapy was started, but bone multiple metastases developed. After she received 30 Gy of radiotherapy, her pain improved. She died of cancer 5 years and 4 months after her initial pancreaticoduodenectomy, which was 3 years and 4 months after her initial pulmonary resection. We identified 14 other case reports of long-term survivors of distal bile duct carcinoma.

    • 1 November 2015
      • Vol. 42  (12) , 2288-90

    [Recurrence of Rectal Cancer with Submucosal Invasion in the Bone and Lymph Nodes 89 Months after Surgery--A Case Report].

    by Takashi Takenoya, Yoji Nishimura, Masako Asayama, Michitoshi Takano, Yoshihiro Mori, Hideki Ishikawa, Yusuke Nishizawa, Takashi Fukuda, Shinsuke Kazama, Katsumi Amikura, et al.

    A woman in her 60s showed positive results on a fecal occult blood test and consulted her doctor. Early-stage cancer of the lower rectum was diagnosed, and a transanal local excision was performed. Histopathological examination revealed that the depth of submucosal invasion was ≧1,000 mm, and the submucosal invasive part of the tumor was a poorly differentiated adenocarcinoma. Therefore, she was referred to our hospital for additional resection. Intersphincteric resection was performed 11 months after the initial operation. The cancer stage was T1N0M0, Stage Ⅰ(UICC 7th edition), and the cancer did not recur. The patient visited our hospital again, 78 months after the additional resection, because of left hip-joint pain. Positron-emission tomography revealed fluorodeoxyglucose uptake in the left acetabulum, para-aortic lymph nodes, and left external iliac lymph nodes; these findings indicated recurrence of the rectal cancer. The patient received radiation therapy (57 Gy) and FOLFIRI; bevacizumab was added from the third course onward. The therapy reduced the size of the tumor recurrence in the bone. This was a rare case of rectal cancer with submucosal invasion that showed recurrence in the bone and lymph nodes 78 months after the additional resection.

  • Open Access

    A Case Report of Adenocarcinoma of the Nasal Cavity in a Patient who Survived for Over 4 Years after Four Liver Metastasis Recurrences Requiring Hepatectomy

    by Satoshi Nakamura, Hirohiko Sakamoto, Amane Takahashi, Katsumi Amikura, Yoshiyuki Kawashima, Ayataka Ishikawa, Yoichi Tanaka

    症例は42歳の男性で,2005年に右鼻腔癌に対して,右鼻腔腫瘍摘出術を施行した.病理組織学的所見はadenocarcinoma,pT1,cN0,cM0,pStage Iで,術後予防的に放射線照射50 Gy施行し,原発巣はCRとなった.2010年に初回肝転移再発を認め,肝外側区域切除術,肝部分切除術(S2,S4)を施行した.その後,肝転移再発に対して,2012年に肝前腹側区域切除術,肝部分切除術(S4,S7),2013年に肝部分切除術(S1,S6,S7,S8),2014年に残肝前区域切除術,肝部分切除術(S6)を施行し,初回肝転移再発後4年の生存を得ている.鼻腔癌は頭頸部癌の中で頻度が低く,鼻腔腺癌はまれな組織型とされる.また,鼻腔腺癌の肝転移単独の再発症例報告は極めてまれで,肝転移巣を切除した報告はない.鼻腔腺癌の肝転移に対して,積極的な肝切除が有効であった1例を報告する.


  • A case of iliac bone metastasis in a hepatocellular carcinoma patient who survived for more than five years after radiotherapy

    by Katsumi Amikura, Hirohiko Sakamoto, Amane Takahashi, Toshiro Ogura, Kiyohiko Omichi, Yoichi Tanaka

    症例は50歳男性.10年以上前HBs-Ag(+)指摘されたが未治療.上腹部痛を主訴に受診.AFP 16.1 ng/ml, PIVKA II 454 mAU/ml, S5/8に70 mm単発の肝細胞癌と診断し,肝前区域切除術施行.術後10カ月CTで単発右腸骨転移(溶骨性,骨外増殖,65×45 mm)を診断された.肝内再発なし.AFP 4454.3 ng/ml, PIVKA II 60.0 mAU/ml.放射線治療51 Gy(3 Gy×17回)/23日間(10 MVリニアックX線,非対向斜入2門),ゾレドロン酸4 mg×5回投与後,疼痛は改善し,腫瘍マーカーも正常化した.CT上,再骨化したままRECIST規準でSDと判断した.骨転移診断から6年後の現在,肝内病変なく長期SDを継続し生存中である.肝細胞癌骨転移の多くは予後不良だが,肝予備能良好,肝内病変なしあるいは制御可能,単発骨転移などで長期生存の報告があり,長期予後を前提とした集学的治療の検討が必要である.